Case reports vs. trial data

Stopping a GLP-1: Mania, Psychosis and Regain

📄 10 PubMed citations

A viral post says quitting tirzepatide can trigger a manic episode. The source is two case reports. Here is what they show, what they cannot show, and what the large trials report on mood and weight after stopping.

Where to buy · affiliate link
Tirzepatide 30 mglisted as GLP-2 TZ at Veratis$95

Code HIGHPEPTIDES takes 15% off at checkout: $80.75

Third-party COA on every lotIn stockShips in the lower 48, $15 standard
Buy tirzepatide at Veratis →

Affiliate link: HighPeptides earns a commission on orders. Research use only. Educational content, not medical advice.

🔬 We read the case report itself rather than the post about it. The post cites DOI 10.4088/PCC.26cr04215, which does not resolve. The paper is Horien et al., Acute Onset of Mood and Psychotic Symptoms After Rapid Discontinuation of a GLP-1 Agonist, Prim Care Companion CNS Disord 2026, DOI 10.4088/PCC.26cr04314 (PMID 42945438). Details the post left out, such as both men's prior psychiatric diagnoses, are on this page.
2
Patients in the viral case report, both with a prior psychiatric diagnosis
0.6%
Reported suicidal ideation on tirzepatide and on placebo (SURMOUNT 1-3 pooled)
14%
Weight regained in 52 weeks after switching tirzepatide to placebo (SURMOUNT-4)

Still logging injections in your Notes app?

A notes thread can't show a missed day at a glance, because it's a list, not a calendar. A printed log can. Your compounds and dates filled in: injection log, weekly schedule, dated calendar. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →
Still shallow lake under a blue sky with scattered clouds and a clump of golden reeds
Photo: Hervé S, France · CC BY-SA · source

What the Case Report Actually Says

🩺
Case 1: psychosis, then catatonic depression

A 61-year-old man with a history of depression, MASH cirrhosis and stage 3a kidney disease stopped tirzepatide in August 2025 because of nausea. In October 2025 he presented with low mood, paranoia, auditory and visual hallucinations and Cotard delusion. Drug screens, spinal fluid, brain MRI and EEG were unremarkable. Psychosis resolved on antipsychotics; he was readmitted weeks later for depression with catatonic features and received electroconvulsive therapy (PMID 42945438).

⚡
Case 2: a manic episode

A 52-year-old man with a history of anxiety stopped tirzepatide abruptly in September 2025 after losing 100 lb over 6 months. He had increased his marijuana use in the weeks before he presented in October 2025 with mania: disorganized, hyperverbal speech, grandiosity, impulsivity and irritability. His vitamin B12 was low (160 pg/mL) and MRI showed old lacunar infarcts that the authors say did not explain the picture. He was started on risperidone (PMID 42945438).

🔍
What the authors conclude

The authors call it plausible that stopping may contribute to acute mood or psychotic symptoms in a select group of at-risk patients, and describe abrupt cessation as one potential precipitant within a multifactorial process. They also write that there are likely many more patients who stopped quickly and had no acute symptoms, and that the psychiatric effects of discontinuation remain poorly characterized (PMID 42945438).

📣
What the viral version dropped

The post presents the cases as a warning about stopping. It leaves out that both men had prior psychiatric diagnoses (depression and anxiety), that the second man had increased marijuana use and a low B12 level, and that the authors frame stopping as one possible factor among several. Two case reports cannot show cause or give a rate (PMID 42945438).

What the Data Shows

Switched to placebo
SURMOUNT-MAINTAIN, needed rescue tirzepatide
67%
Stepped down to 5 mg
SURMOUNT-MAINTAIN, needed rescue tirzepatide
25%
Stayed on top dose
SURMOUNT-MAINTAIN, needed rescue tirzepatide
8%
Weight regained after stopping semaglutide
STEP 1 extension, 11.6 of 17.3 points lost
67%

Key Takeaways

What We Know
  • Two case reports describe men hospitalized with psychosis or mania one to two months after stopping tirzepatide; a case report cannot show that stopping caused it (PMID 42945438).
  • Both men had a prior psychiatric diagnosis, and the second had increased marijuana use and a low vitamin B12 level (PMID 42945438).
  • In pooled STEP 1, 2, 3 and 5 data, semaglutide 2.4 mg did not raise depressive symptoms or suicidal ideation compared with placebo in people without known major psychopathology (PMID 39226070).
  • In pooled SURMOUNT-1, -2 and -3 data, 0.6% of both the tirzepatide and placebo groups reported suicidal ideation, and depressive symptom scores were slightly lower on tirzepatide (PMID 41537305).
  • Weight regain after stopping is well documented: STEP 1 participants regained 11.6 of the 17.3 percentage points they had lost within a year of stopping semaglutide (PMID 35441470).
  • A 2026 BMJ meta-analysis of 37 studies found average regain of 0.4 kg a month after stopping weight-management drugs, with cardiometabolic markers projected back to baseline within 1.4 years (PMID 41500720).
  • Stepping down to tirzepatide 5 mg kept more weight off than switching to placebo in SURMOUNT-MAINTAIN: -16.6% vs -9.9% from baseline at week 112 (PMID 42119587).
What We Don't Know
  • Whether stopping a GLP-1 drug causes mania or psychosis at all. There is no rate, only two published cases (PMID 42945438).
  • How often manic or hypomanic symptoms occur on or after these drugs: a 2026 systematic review found they were not systematically assessed in the included studies (PMID 42793351).
  • Risk for people with bipolar disorder or a psychotic disorder: the trial analyses covered people without known major psychopathology (PMID 39226070, PMID 41537305).
  • Whether a structured taper prevents weight regain; a 2026 review says this remains unknown and needs prospective study (PMID 42396734). The psychiatric effects of stopping are also poorly characterized (PMID 42945438).
  • The mechanism. The case report authors say how GLP-1 drugs act on the brain is unclear (PMID 42945438).

Frequently Asked Questions

Can stopping tirzepatide cause mania or psychosis?

It has not been shown. A 2026 case report describes two men admitted with psychosis or mania one to two months after stopping tirzepatide (PMID 42945438). Both had prior psychiatric diagnoses, and one had increased marijuana use and low vitamin B12. The authors call stopping one possible factor in a multifactorial process and note that many people likely stop quickly with no acute symptoms.

Do GLP-1 drugs like semaglutide or tirzepatide cause depression or suicidal thoughts?

Pooled trial data do not show that. Semaglutide 2.4 mg did not increase depressive symptoms or suicidal ideation versus placebo in STEP 1, 2, 3 and 5 (PMID 39226070), and suicidal ideation was 0.6% on both tirzepatide and placebo in SURMOUNT-1 to -3 (PMID 41537305). In a large health-record study, semaglutide was linked to lower risk of new suicidal ideation than non-GLP-1 weight-loss drugs (HR 0.27) (PMID 38182782). A 2026 review rated the certainty of this evidence low to very low (PMID 42793351).

How much weight comes back after stopping a GLP-1?

In STEP 1, about two-thirds within a year. One year after stopping semaglutide, STEP 1 participants had regained 11.6 of the 17.3 percentage points they lost (PMID 35441470). In SURMOUNT-4, people switched from tirzepatide to placebo regained 14.0% of body weight over 52 weeks, while those who stayed on it lost a further 5.5% (PMID 38078870). A BMJ meta-analysis put average regain at 0.4 kg a month (PMID 41500720).

Is it better to taper off tirzepatide than stop abruptly?

For weight, a lower dose beats stopping in one trial: in SURMOUNT-MAINTAIN, 25% of people stepped down to 5 mg needed rescue tirzepatide, compared with 67% of those switched to placebo and 8% of those who stayed on the top dose (PMID 42119587). Whether a taper that ends in stopping prevents regain remains unknown (PMID 42396734), and the psychiatric effects of stopping are poorly characterized (PMID 42945438). Any change should be planned with the prescriber.

Who should be most careful when stopping a GLP-1?

The case report authors point to people with a prior psychiatric history, since both of their patients had one, and suggest prescribers watch for neuropsychiatric symptoms when the drug is stopped (PMID 42945438). Trial safety data mostly come from people without known major psychiatric illness (PMID 39226070), so anyone with bipolar disorder or a psychotic disorder has less data to go on.

Research-Grade Source

Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify). HighPeptides' primary vendor reference for peptides.

Browse Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost.

Peer-Reviewed References

Source 1
Acute Onset of Mood and Psychotic Symptoms After Rapid Discontinuation of a GLP-1 Agonist.
Prim Care Companion CNS Disord · 2026
PMID: 42945438
Source 2
Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.
JAMA Intern Med · 2024
PMID: 39226070
Source 3
Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.
Obesity (Silver Spring) · 2026
PMID: 41537305
Source 4
Association of semaglutide with risk of suicidal ideation in a real-world cohort.
Nat Med · 2024
PMID: 38182782
Source 5
Neuropsychiatric Outcomes Associated with GLP-1 Receptor Agonists in Adults with Overweight or Obesity: A Systematic Review.
Brain Sci · 2026
PMID: 42793351
Source 6
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Diabetes Obes Metab · 2022
PMID: 35441470
Source 7
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
JAMA · 2024
PMID: 38078870
Source 8
Weight regain after cessation of medication for weight management: systematic review and meta-analysis.
BMJ · 2026
PMID: 41500720
Source 9
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
Lancet · 2026
PMID: 42119587
Source 10
Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies.
Diabetes Obes Metab · 2026
PMID: 42396734
Ebook
The Complete Peptide Protocol Guide

67-page guide: protocols, dosing, sourcing. Everything in one place.

Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) All ebooks & guides →
Disclaimer

Educational purposes only. Not medical advice.

Do not stop or change a prescribed medication without talking to the prescriber.

If you or someone you know is in crisis or thinking about self-harm, call or text 988 in the US.

📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.